Faqs.org homepage
::
Abstracts index
Abstracts: Not cricket. Zhu Rongji in the land of demons. Between guns and economics
Abstracts: Not dead yet: Microsoft and antitrust. Too hard on Microsoft. Mad at Microsoft: computer software
Abstracts: Note: alternative treatments of congestion in DEA - a response to the Cherchye, Kuosmanen and Post critique. Comparisons and evaluations of alternative approaches to the treatment of congestion in DEA
Abstracts: Not everyone is ignoring the fate of Hongkong's Legco. Everyone's wearing long hair now. When your belly belongs to everyone
Abstracts: Not exactly one nation. Iron constitution. Australia's populist bites back
Abstracts: Not forgotten, not forgiven. A counter-revolutionary's quest for the truth. Still squealing
Abstracts: Not forgotten, not forgiven. Political business. The new spin
Abstracts: Not frothy, but fairly liquid. Pantling's quick promotion. Willes makes waves at Close Brothers
Abstracts: Not guilty. Jack Straw takes on the law. Straw condemns the juries
Abstracts: Not half bad. The leaky bucket. Maybe this time
Abstracts: No thanks: Seoul resists sending more rice to North Korea. Opening up the clam. The price of unity
Abstracts: No, thanks. Space, indoor frontier. Novel strategy
Abstracts: Not here. The battle with AIDS. Thirty-six places to go
Abstracts: Nothing is really private in Vietnam. The price of everything, the value of nothing. Double or nothing
Abstracts: Nothing like the sun: Pasona's chief isn't your typical Japanese CEO. Comic relief: Japanese comedienne battles prejudice with humour
Abstracts: Nothing to declare: the political void in Afghanistan has spawned a vast smugglers' market that is crippling Pakistan's economy and threatens those of other nations in the region
Abstracts: Nothing to fear but fear itself. Small cause. Oh what a lovely millenium bug
Abstracts: Not hopeless: Bosnia. Peace in the hands of the unpeaceful Serbs. Pieces of a peace: ex-Yugoslavia
Abstracts: No thorns. Guns and money: illicit arms trade puts China on the defensive. After the fact: Pentagon to probe hi-tech transfer to China
Abstracts: No time for a siesta. Buyout backers begin to cash in. No longer just 'nice to have'
Abstracts: No time for planning. Enhancement in conservation areas. Managing old towns
Abstracts: No time for play. Drawn upwards. Selecting for the best
Abstracts: NO TIME FOR THE GOLD AND THE BEAUTIFUL. GLOBAL JUTE OUTPUT LIKELY TO FALL FOOD INDUSTRY STILL IN PROCESSING STAGE
Abstracts: No Time to Lose. Crime Time. Movement's a Must
Abstracts: Not in the cards. Fat chance. Ad speak 101
Abstracts: Not just alms. Eat your greens. China on a roll. The car-finance market in China takes off as the middle class discovers a passion for cars
Abstracts: NOT JUST A PAINT JOB. TRUE PAINT, NOT GLOSS
Abstracts: Not just hot air. A mighty defence and aerospace merger. EUROPE: AIRBUS HOLDS TALKS WITH JAPANESE
Abstracts: Not making it. Adopt brace position. What a peculiar cycle
Abstracts: Not much to smile about; talks on Northern Ireland's future are in trouble even before they begin. Musical chairs
Abstracts: Not much to yell about. ING spreads its wings. Crossing sectors, crossing borders
Abstracts: Not nice in Nice: France. Undoing France. Elisabeth Guigou, a rising force in France
Abstracts: NOT NOW DARLING. SITA IN TALKS WITH AAI FOR AIRPORT MANAGEMENT TOOLS. KARNATAKA, TATAS MOVE TO REVIVE AIRPORT PLAN
Abstracts: Not of delight. Going nowhere. Grinding to a halt
Abstracts: Not only silver in trade. CKD Blansko has a new owner. Czech Republic: State expenditures on environmental maintenance
Abstracts: Not quite the monster they call it. Making the desert bloom. Downtown is up
Abstracts: Not required. Forced devotion. New hurdles
Abstracts: No truck with trains: China's joint ventures take to the highway. The changing marketplace: an operator's perspective
Abstracts: No trust. Meeting their maker. Audience appeal: Italy
Abstracts: Not Soane's idea of domestic bliss. Tensions that lie beneath the surface. The ever-changing city
Abstracts: Not so caring. Storm clouds from Brazil. Europe's summertime blues
Abstracts: Not so fair pay. Paying the price. Jobs and wages revisited
Abstracts: Not so fast: Malaysian growth slows from breakneck pace. On an even keel. Hey, big spenders: Malaysia's consumers worry economic planners
Abstracts: Not-so-fine print: Nafta's details may exclude Asian traders. Caught in the crossfire
Abstracts: Not so Grimm: a cautionary tale about Eastern Europe. Over the sea to Spain. Will Western Europe receive the great unwashed - one day?
Abstracts: Not so high, nor so painful. Gloom at the Bank. Don't rush for the exits
Abstracts: Not so liberal: Hong Kong. Patten's Chinese torture. Patten on parade: Hong Kong
Abstracts: Not so liberal: Hong Kong. Patten sets the path. New medicine for Hong Kong
Abstracts: Not so neighborly: American banks. The banker's burden. Debt and taxes: Japanese banks
Abstracts: Not so special: Bavaria. Bohemia's raddled face. Propinquity pays: Bavaria and Bohemia
Abstracts: Not so super markets: retailing. Europe's discount dogfight. Bourses for courses: European financial markets
Abstracts: Not so tough: the economy. Budget in brief. Virtuous unreality
Abstracts: Not such a balanced outcome: coping with a hung parliament. The importance of being Labour. Will it be a landslide? It would take a miracle to save the Tories on May 1st
Abstracts: Not such an extreme year. Taking time to refine a buyout. From real ale to car care
Abstracts: Not the human genome project. The genetic illusion. The end of the beginning
Abstracts: Not there yet: Mexico. Bad old ways? Mexico. Fox's moment of truth
Abstracts: Not this again, please. As Japan goes? Open Japan's skies: a trade row with America over air services will be a good test of Japan's willingness to deregulate the economy
Abstracts: Not waving but drowning. Credit where it's due. The rescue squad: With murmurs of an economic downturn around the corner, companies need to keep a vigilant eye on their cashflow. But financial distress need not spell the end for your company
Abstracts: Not yet giving thanks. Let fly. Time and money
Abstracts: Not yet ready to go it alone. Crunch time in Jakarta. Noodles top the menu
Abstracts: Not your dad's car anymore. The kings of radio. The same old sod
Abstracts: Not your mom's pizza. Planning with pictures. Christmas eye
Abstracts: Nouns versus adjectives in country-of-origin communications. A comparison of ratings methods: telephone versus diary
Abstracts: Nourish your body with sunshine foods. Lose 12 pounds in June with our antioxidant-packed rainbow diet. The antioxidant diet
Abstracts: Nova Hut in 2000. Carborundum Electrite increases proceeds. Hedva increased its proceeds in 2000
Abstracts: Novartis AG. Novartis suffers another setback for Prexige debut
Abstracts: Novartis angers critics in India: challenge of patent laws creates uproar among public-health advocates. Lawsuit is filed against Novartis on Ritalin sales
Abstracts: Novartis buys 20% stake in Roche for C3.12 billion (Euro dollars). Roche, DeCODE set research pact
Abstracts: Novartis CEO goes public with pitch on Aventis deal: in unusual move, Vasella attempts to put pressure on the French government
Abstracts: Novartis comes to rescue of neurotic dogs. U.S. approves Glaxo treatment for depression. AstraZeneca's Crestor should get U.S. approval
Abstracts: Novartis drug approved by EU. Novartis has potential blockbuster as FDA backs blood-pressure drug. Novartis to sell Prilosec copy in U.S
Abstracts: Novartis explores options on Aventis; giant Swiss drug maker weighs white knight role aimed at thwarting Sanofi
Abstracts: Novartis first-half results beat analysts' expectations. Novartis posts sales slide, warns of profit slowdown
Abstracts: NOVARTIS INDIA: WORLD LEADER SMITHKLINE BEECHAM. SBEC SUGARS
Abstracts: Novartis launches buyback of shares. Novartis expands generics range for $8.4 billion. Shareholder insurrection infects Novartis's $5.1 billion Chiron bid
Abstracts: Novartis names CEO Vasella to be next chairman. (Daniel Vasella succeeds Alex Krauer). Sanofi outs operating chief Guerin (Sanofi Synthelabo SA's COO Herve Guerin)
Abstracts: Novartis offers to buy rest of Chiron. Novartis agrees to acquire the rest of Chiron for $5.1 billion. Biotech industry heads toward IPO boomlet
Abstracts: Novartis posts 17% profit rise on a 12% increase in revenue. UBS is likely to post dismal results
Abstracts: Novartis reaches a crossroads as drug sales dwindle. Drug firms battle for pre-eminence in marketing of multiple sclerosis drug
Abstracts: Novartis reports two heart drugs are safe, effective. Novartis profit increases 11% on strong sales. Roche posts 24% rise in net, sets optimistic sales forecast
Abstracts: Novartis reports two heart drugs are safe, effective. Swiss Re names former official of Federal Reserve to its board
Abstracts: Novartis seeks approval to use Gleevec in four rare cancers. Sanofi aims to sell obesity drug this year, despite FDA setback
Abstracts: Novartis, SGX pair up to develop leukemia drugs. AstraZeneca pipeline suffers another blow. AstraZeneca signs deal with RNAi company: medical giant will invest money to help develop treatments
Abstracts: Novartis shakes ranks as earnings flag: management swap, job cuts aim to cope with shifts in market. European drug makers post strong third-quarter results
Abstracts: Novartis's net profit rises 13%, driven by a 19% sales increase. Swiss Life net drops as capital gains fall
Abstracts: Novartis's new marker-gene system targets genetically modified crops. Novartis unveils restructuring of its main drug division
Abstracts: Novartis takes scythe to Agrochem division; plan to slash 1,100 jobs seen reaping bumper. Degussa to cut jobs, maintains 2001 forecast
Abstracts: Novartis talks to Aventis about white-knight offer: preliminary discussions come as French drug maker tries to fight off Sanofi bid
Abstracts: Novatek offer lures investors back to Russia. Suez net climbs on pricing gains; eyes GdF tie-up. Possible power crunch in Norway could hurt U.K
Abstracts: Novell's net income plunged by 83% in third quarter. Software says pretax earnings surged in quarter. Business Objects' profit doubled in last quarter
Abstracts: Novel types of sensitivity analysis for additive MCDM methods. Using investment protfolio return to combine forecasts: A multiobjective approach
Abstracts: No venture, no gain. Skirting the potholes. Switched-on tycoon
Abstracts: Novice investors learn lesson; once-burned Hong Kong stock pickers now take conservative tack. Investors watch closely for finance gauge
Abstracts: NOVO NORDISK TO FUND ENZYME PROJECT OF MYSORE VARSITY IDBI, BAJAJ GO IN FOR BIG US-64 REDEMPTIONS. LIC'S INVESTMENTS IN EQUITIES SHOOT UP TO Rs1,907 CR
Abstracts: Novo's pretax profit fell in quarter, but results still exceeded forecasts. Novo Nordisk says pretax profit rose 44% in first half
Abstracts: No wait at Martha's Cafe. Winning isn't everything. My new, special sister
Abstracts: Now another go at self-reform. Repression, reform, or both? The humbling of Chubais
Abstracts: No way out, at least not an easy one. Before the flood. How to get into women's clothing ...
Abstracts: No way to treat an energy rating. Coffeehouse conversation. The power to change: At the close of the Part L constitution, a speech put things in perspective by examining the meta-narratives of energy policy
Abstracts: Now bust Microsoft's trust. After the verdict. Deadly embrace
«
previous page
next page
»
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.